打开APP
userphoto
未登录

开通VIP,畅享免费电子书等14项超值服

开通VIP
Answer
userphoto

2022.12.30 加拿大

关注

“Can” we use? Sure. But SHOULD we use…..??

To answer this question I would respectfully reply that I will go with what the evidence has shown to be effective in reducing the severity or progression (or even to “cure”) the disease. And this evidence should conform to established scientific method. The very least of which should include the ability to be reproduce the results in numerous subjects, preferably in a myriad of types of subject patients.

To date neither of these substances have in any stretch shown to provide this level of evidence. Therefore I would humbly submit the “should not” be used in patients infected with with COVID-19.

As an aside I would not classify hydroxychloroquine as a homeopathic medicine. As I understand this class of therapies it could not be considered as such.

It is traditionally classified as a DMARD (Disease-modifying antirheumatic drug). It is believed to interfere with parasitic vesicle functions and phospholipid metabolism by increasing pH, interrupting plasmodial erythrocyte stages (antimalarial); inhibits rheumatoid factor, acute phase reactants and various enzymes (antyirheumatic/immunosuppression) .

(No, I didn’t know that by heart. I had to look it up…….just trying to look smart)

My point is with some practitioners expounding its use in COPVD-19 there developed a shortage for patients that the drug actually has evidence for use in.

This to me is unacceptable. If you care for patients (literally or figuratively) base your decisions on evidence .

Stay healthy.

本站仅提供存储服务,所有内容均由用户发布,如发现有害或侵权内容,请点击举报
打开APP,阅读全文并永久保存 查看更多类似文章
猜你喜欢
类似文章
【热】打开小程序,算一算2024你的财运
little/very little few/very few a little/a few
大剂量吸入皮质类固醇与慢性阻塞性肺疾病患者出现肺结核有关
No way表示“没门儿”,in no way也是“没门儿”?别用错了哦
每日一词:placebo
Depression in adults: in association with NICE : Page 23
以后再有人让你算24点,翻出这张表来就行了(仅限四则...
更多类似文章 >>
生活服务
热点新闻
分享 收藏 导长图 关注 下载文章
绑定账号成功
后续可登录账号畅享VIP特权!
如果VIP功能使用有故障,
可点击这里联系客服!

联系客服